Conferences - Results from #6820

SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - PRO December 3, 2018

SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - CON December 3, 2018

SUO 2018: Hereditary Kidney Cancer and Genetic Testing December 2, 2018

SUO 2018: Long-term Outcomes of Active Surveillance for Prostate Cancer – The Memorial Sloan Kettering Cancer Center Experience December 2, 2018

SUO 2018: Post-Operative Opioid Prescribing in Urology: Are We Contributing to The National Crisis? December 2, 2018

SUO 2018: Cytoreductive Nephrectomy Is No Longer Standard of Care in Patients with Metastatic Renal Cell Carcinoma December 2, 2018

SUO 2018: An Oncolytic Adenovirus, for BCG-unresponsive Non-muscle-invasive Bladder Cancer (NMIBC): 18-month Follow-up from a Multicenter Phase II Trial December 2, 2018

SUO 2018: Surgical Perspective on Management for Hereditary Kidney Cancer December 2, 2018

SUO 2018: A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Enzalutamide in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of PROSPER by Prior Definitive Surgery December 2, 2018

SUO 2018: Before and After Clinical CR from NAC December 2, 2018

SUO 2018: There Is Still a Role for Cytoreduction December 1, 2018

SUO 2018: Qualitative and Quantitative Evidence of Sipuleucel-T Induced PAP and PA2024 Specific CD8+ Cytolytic Response and its Association with Overall Survival December 1, 2018

SUO 2018: Changing Practice in High Risk Prostate Cancer Using Novel Trial Design: The STAMPEDE Study December 1, 2018

SUO 2018: Impact of Robotics - The Changing Face of Urologic Oncologic Surgery from 2000-2018 December 1, 2018

SUO 2018: Phase 2 Study of Pembrolizumab Monotherapy for High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): Results from Keynote-057 December 1, 2018

SUO 2018: The Case for Neoadjuvant Immunotherapy December 1, 2018

SUO 2018: The Case for Adjuvant Immunotherapy December 1, 2018

SUO 2018: Adaptive Survival Pathways – AR Variants and Autophagy December 1, 2018

SUO 2018: Preclinical Models in Bladder Cancer and Translational Research December 1, 2018

SUO 2018: Uptake on PSMA Targeted Alpha Emitters in mCRPC December 1, 2018

Page 342 of 594